Prosecution Insights
Last updated: May 29, 2026

Kymab Limited

10 pending office actions • 5 art units • 6 examiners • 0 of 10 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
5
Non-Final OAs
5
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
3
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 30 days (3)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
5
Medium (50%)
1
Easy (10%)
4
Unknown (40%)

Rejection Statute Mix

BucketCases
§103 only4 (40%)
§112 only1 (10%)
Double-patenting + other1 (10%)
No statute on record4 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
OUSPENSKI, ILIA I 3 77.6% +20.3%
HADDAD, MAHER M 2 50.4% +54.3%
SINGH, ANOOP KUMAR 2 42.8% +67.6%
ROONEY, NORA MAUREEN 1 60.5% +23.2%
HOLLAND, PAUL J 1 57.5% +64.7%
LEE, YIE CHIA 1 72.7% +43.4%

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17727309 ANTI-ICOS ANTIBODIES OUSPENSKI, ILIA I 204d overdue
18512687 METHODS, CELLS & ORGANISMS HOLLAND, PAUL J 140d overdue
18592425 ANTI-PD-L1 AND IL-2 CYTOKINES ROONEY, NORA MAUREEN 42d overdue
18284952 THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING LEE, YIE CHIA 23d overdue
18162043 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 3d overdue
18364906 ANTIBODIES, USES & METHODS HADDAD, MAHER M 7d
17725228 SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD OUSPENSKI, ILIA I 12d
16905537 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 22d

Top Art Units

Art UnitApps
1641 3
1644 3
1632 2
1656 1
1642 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18592425 ANTI-PD-L1 AND IL-2 CYTOKINES ROONEY, NORA MAUREEN 1641 §103 Non-Final OA 42d overdue Pending Feb 29, 2024
18512687 METHODS, CELLS & ORGANISMS HOLLAND, PAUL J 1656 Other Final Rejection 140d overdue Pending Nov 17, 2023
18284952 THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING LEE, YIE CHIA 1642 §112 Non-Final OA 23d overdue Pending Sep 29, 2023
18459995 ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS HADDAD, MAHER M 1641 §103 Final Rejection 26d Pending Sep 01, 2023
18364906 ANTIBODIES, USES & METHODS HADDAD, MAHER M 1641 Other Final Rejection 7d Pending Aug 03, 2023
18174925 BISPECIFIC ANTIBODY FOR ICOS AND PD-L1 OUSPENSKI, ILIA I 1644 DPOther Final Rejection 63d Pending Feb 27, 2023
18162043 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 1632 §103 Final Rejection 3d overdue Pending Jan 31, 2023
17727309 ANTI-ICOS ANTIBODIES OUSPENSKI, ILIA I 1644 Other Non-Final OA 204d overdue Pending Apr 22, 2022
17725228 SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD OUSPENSKI, ILIA I 1644 Other Non-Final OA 12d Pending Apr 20, 2022
16905537 Animal Models and Therapeutic Molecules SINGH, ANOOP KUMAR 1632 §103 Non-Final OA 22d Pending Jun 18, 2020

Managing Kymab Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month